Lyell lays off 25% of staff and CMO leaves as company foreshadows first clinical data next year
Lyell Immunopharma is laying off 25% of its workforce, and its chief medical officer is leaving, according to the Bay Area biotech company’s third-quarter report.
The company had 274 employees as of December of last year. It declined to specify how many workers are part of the layoffs.
“We have restructured our company to prioritize investment in our clinical-stage programs and core research platforms and have streamlined operations,” Lyell president and CEO Lynn Seely said in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.